Lunglmayr G, Maier U, Spona J
Andrologia. 1983;15 Spec No:548-53.
The effect of bromocriptin on semen parameters and endocrine profiles in 25 males presenting idiopathic oligozoospermia was evaluated in a prospective controlled clinical trial versus 25 patients treated with placebo. Following results were obtained: a) Serum concentrations of prolactin decreased significantly during bromocriptin treatment while FSH, LH and Testosterone concentration remained unchanged. b) Sperm count, motility and morphology were not significantly affected by bromocriptin versus placebo. c) Conception rate was not significantly different between the treatment and placebo group. From the results of this study it can be concluded that bromocriptin is no suitable agent in the treatment of idiopathic, normoprolactinemic oligozoospermia.
在一项前瞻性对照临床试验中，评估了溴隐亭对25例特发性少精子症男性精液参数和内分泌状况的影响，将其与25例接受安慰剂治疗的患者进行对比。获得了以下结果：a）在溴隐亭治疗期间，催乳素的血清浓度显著下降，而促卵泡激素（FSH）、促黄体生成素（LH）和睾酮浓度保持不变。b）与安慰剂相比，溴隐亭对精子计数、活力和形态没有显著影响。c）治疗组和安慰剂组的受孕率没有显著差异。从这项研究的结果可以得出结论，溴隐亭不适用于治疗特发性、催乳素正常的少精子症。
